Clinical Trials Directory

Trials / Unknown

UnknownNCT02898376

Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer

Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
142 (estimated)
Sponsor
Institut de Cancérologie de Lorraine · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the dermatological life quality six months after spa cares in patients with severe late toxicity involving the skin and / or soft tissues after postoperative radiotherapy for breast cancer. Half of the patients will be treated with a combination of pentoxifylline (PTX) and alpha-tocopherol (Vit E) when Half of the patients will receive skin-oriented spa cares in addition.

Detailed description

The combination of PTX and vit E appears as the standard treatment of radiation induced fibrosis. Synergism between PTX and Vit E is likely, as treatment with each drug alone is ineffective. This combination was also positively evaluated in the treatment of osteoradionecrosis, radiation-induced pelvic neuropathies, pneumoniae as well as bowel pathologies. Spa cares are part of the standard treatment of burn scars. Two spa treatments per year enable the mitigation or disappearance (after several treatments) of pruritus, dysesthesia, local inflammation, hypertrophy and sclerosis. They promote the healing of chronic superficial erosions. The spa treatment combines baths, sprays and especially filiform showers with thermal water jets under high pressure for a few minutes.

Conditions

Interventions

TypeNameDescription
OTHERskin-oriented spa carestandardized procedure : 72 care sessions over 18 days of treatment +/- Additional care according to the specificity of each spa
DRUGPentoxifylline400 mg bid during at least 6 months
DRUGTocopherol acetate500 mg bid during at least 6 months

Timeline

Start date
2018-12-01
Primary completion
2020-07-01
Completion
2021-12-01
First posted
2016-09-13
Last updated
2018-08-08

Locations

21 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02898376. Inclusion in this directory is not an endorsement.